Satoshi Konagai - Concepedia

Author

Satoshi Konagai

Also Known As

S. Konagai, Satoshi Konagai

Publications

149

Citations

H-Index

Concepts

All Affiliations

Satoshi Konagai is an author at Astellas Pharma (Japan) specializing in tumor biology, cancer cell biology, and medicine.

#	Concept	H-Index	Publications	Citations
1	Medicine	4	4	107
2	Cell Biology	4	4	107
3	Pharmacology	4	4	107
4	Immunology	1	1	57
5	Pathology	1	1	20

Satoshi Konagai

Publications

124

Citations

H-Index

Page 1

	Year	Citations
The Selective Anaplastic Lymphoma Receptor Tyrosine Kinase Inhibitor ASP3026 Induces Tumor Regression and Prolongs Survival in Non–Small Cell Lung Cancer Model Mice Masamichi Mori, Yoko Ueno, Satoshi Konagai, Molecular Cancer Therapeutics Eml4 GenesImmunologyCancer BiologyTumor BiologyAlk-driven Nsclc	2014	57
Abstract 1728: ASP8273, a novel mutant-selective irreversible EGFR inhibitor, inhibits growth of non-small cell lung cancer (NSCLC) cells with EGFR activating and T790M resistance mutations Hideki Sakagami, Satoshi Konagai, Hiroko Yamamoto, Cancer Research Abstract 1728PathologyCancer BiologyTumor BiologyOncology	2014	20
Mutant-Selective Irreversible EGFR Inhibitor, Naquotinib, Inhibits Tumor Growth in NSCLC Models with EGFR-Activating Mutations, T790M Mutation, and AXL Overexpression Hiroaki Tanaka, Hideki Sakagami, Naoki Kaneko, Molecular Cancer Therapeutics	2019	17
Abstract A227: Antitumor activities of ASP3026 against EML4-ALK-dependent tumor models. Sadao Kuromitsu, Masamichi Mori, Itsuo Shimada, Molecular Cancer Therapeutics Inhibitory ActivityMedicinePharmacologyCancer Cell BiologyBronchial Neoplasm	2011	16
Abstract 2821: Anti-tumor activity of ASP3026, – A novel and selective ALK inhibitor - Sadao Kuromitsu, Masamichi Mori, Itsuro Shimada, Cancer Research Cancer BiologyTumor BiologyAsp3026 Treated-miceReceptor Tyrosine KinaseCancer Cell Biology	2011	14

Page 1